

July 6, 2022
Nihon Medi-Physics Co., Ltd.

Nihon Medi-Physics and PeptiDream Agree to Conclude Strategic Alliance for the Discovery & Development of Peptide-based Theranostics

Nihon Medi-Physics Co., Ltd. (“NMP”) announced today that it has mutually agreed with PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”) (TSE Prime Market), to conclude the companies’ strategic alliance for the discovery & development of peptide-radioisotope (RI) conjugates for use as therapeutics and diagnostics as of 6th July, 2022.

In December 2018, NMP and PeptiDream entered into a strategic alliance, with the two companies working together across a variety of programs to conjugate NMP’s radioisotopes with PeptiDream’s constrained peptides to create a new class of therapeutic and diagnostic products. With the conclusion of the strategic alliance, the companies will end all research activities, and NMP has agreed to transfer the shared rights to the collaboration results to the programs to PeptiDream (terms undisclosed).

About Nihon Medi-Physics Co., Ltd.

Nihon Medi-Physics is engaging in ensuring stable supply and research and development of the products as a leading manufacturer of radiopharmaceuticals in Japan. Based on the technological proficiency and trust built over the years, the company is also working on research and development of “Theranostics (a combination of therapy and diagnosis),” which is a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. The company will continue contributing to society by creating values as a life science company.

Official website: <https://www.nmp.co.jp/eng/index.html>

Contacts

Nihon Medi-Physics Co., Ltd.
General Affairs Group, Corporate Communication
E-mail: nmp_press@nmp.co.jp